Free Trial
→ You cannot escape this reality (From Porter & Company) (Ad)tc pixel Free HBP Stock Alerts

Helix BioPharma (HBP) Competitors

Helix BioPharma logo
C$1.63 0.00 (0.00%)
As of 05/22/2026 03:59 PM Eastern
Compare

HBP vs. FRX, PLI, ABCN, EMC, and TH

Should you buy Helix BioPharma stock or one of its competitors? MarketBeat compares Helix BioPharma with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Helix BioPharma include Fennec Pharmaceuticals (FRX), ProMetic Life Sciences (PLI), VIVO Cannabis (ABCN), Emblem (EMC), and Theratechnologies (TH). These companies are all part of the "biotechnology" industry.

How does Helix BioPharma compare to Fennec Pharmaceuticals?

Fennec Pharmaceuticals (TSE:FRX) and Helix BioPharma (TSE:HBP) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their media sentiment, valuation, analyst recommendations, dividends, risk, profitability, institutional ownership and earnings.

Fennec Pharmaceuticals has a beta of 3.218074, suggesting that its share price is 222% more volatile than the broader market. Comparatively, Helix BioPharma has a beta of 0.403644, suggesting that its share price is 60% less volatile than the broader market.

Fennec Pharmaceuticals has higher revenue and earnings than Helix BioPharma. Fennec Pharmaceuticals is trading at a lower price-to-earnings ratio than Helix BioPharma, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Fennec PharmaceuticalsC$51.00M9.45-C$800.44K-C$0.29N/A
Helix BioPharmaN/AN/A-C$50.55M-C$0.06N/A

12.4% of Fennec Pharmaceuticals shares are owned by institutional investors. Comparatively, 0.0% of Helix BioPharma shares are owned by institutional investors. 16.2% of Fennec Pharmaceuticals shares are owned by insiders. Comparatively, 2.2% of Helix BioPharma shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

In the previous week, Fennec Pharmaceuticals had 11 more articles in the media than Helix BioPharma. MarketBeat recorded 11 mentions for Fennec Pharmaceuticals and 0 mentions for Helix BioPharma. Helix BioPharma's average media sentiment score of 0.00 beat Fennec Pharmaceuticals' score of -0.43 indicating that Helix BioPharma is being referred to more favorably in the news media.

Company Overall Sentiment
Fennec Pharmaceuticals Neutral
Helix BioPharma Neutral

Helix BioPharma has a net margin of 0.00% compared to Fennec Pharmaceuticals' net margin of -17.22%. Helix BioPharma's return on equity of -36.79% beat Fennec Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Fennec Pharmaceuticals-17.22% -58.09% 8.88%
Helix BioPharma N/A -36.79%-279.98%

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Fennec Pharmaceuticals
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
1 Strong Buy rating(s)
4.00
Helix BioPharma
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

Summary

Fennec Pharmaceuticals beats Helix BioPharma on 9 of the 14 factors compared between the two stocks.

How does Helix BioPharma compare to ProMetic Life Sciences?

ProMetic Life Sciences (TSE:PLI) and Helix BioPharma (TSE:HBP) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their analyst recommendations, profitability, media sentiment, institutional ownership, risk, valuation, earnings and dividends.

Helix BioPharma has lower revenue, but higher earnings than ProMetic Life Sciences. Helix BioPharma is trading at a lower price-to-earnings ratio than ProMetic Life Sciences, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
ProMetic Life SciencesC$39.91M0.00-C$1.47B-C$63.06N/A
Helix BioPharmaN/AN/A-C$50.55M-C$0.06N/A

ProMetic Life Sciences' return on equity of 0.00% beat Helix BioPharma's return on equity.

Company Net Margins Return on Equity Return on Assets
ProMetic Life SciencesN/A N/A N/A
Helix BioPharma N/A -36.79%-279.98%

0.0% of Helix BioPharma shares are owned by institutional investors. 2.2% of Helix BioPharma shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

In the previous week, ProMetic Life Sciences' average media sentiment score of 0.00 equaled Helix BioPharma'saverage media sentiment score.

Company Overall Sentiment
ProMetic Life Sciences Neutral
Helix BioPharma Neutral

Summary

ProMetic Life Sciences and Helix BioPharma tied by winning 4 of the 8 factors compared between the two stocks.

How does Helix BioPharma compare to VIVO Cannabis?

VIVO Cannabis (CVE:ABCN) and Helix BioPharma (TSE:HBP) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their profitability, dividends, risk, earnings, analyst recommendations, valuation, media sentiment and institutional ownership.

In the previous week, VIVO Cannabis' average media sentiment score of 0.00 equaled Helix BioPharma'saverage media sentiment score.

Company Overall Sentiment
VIVO Cannabis Neutral
Helix BioPharma Neutral

VIVO Cannabis' return on equity of 0.00% beat Helix BioPharma's return on equity.

Company Net Margins Return on Equity Return on Assets
VIVO CannabisN/A N/A N/A
Helix BioPharma N/A -36.79%-279.98%

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
VIVO CannabisN/AN/AN/AN/AN/A
Helix BioPharmaN/AN/A-C$50.55M-C$0.06N/A

0.0% of Helix BioPharma shares are held by institutional investors. 2.2% of Helix BioPharma shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Summary

VIVO Cannabis and Helix BioPharma tied by winning 2 of the 4 factors compared between the two stocks.

How does Helix BioPharma compare to Emblem?

Helix BioPharma (TSE:HBP) and Emblem (CVE:EMC) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, valuation, dividends, institutional ownership, analyst recommendations, risk, profitability and earnings.

0.0% of Helix BioPharma shares are owned by institutional investors. 2.2% of Helix BioPharma shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Emblem's return on equity of 0.00% beat Helix BioPharma's return on equity.

Company Net Margins Return on Equity Return on Assets
Helix BioPharmaN/A -36.79% -279.98%
Emblem N/A N/A N/A

Emblem has higher revenue and earnings than Helix BioPharma. Helix BioPharma is trading at a lower price-to-earnings ratio than Emblem, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Helix BioPharmaN/AN/A-C$50.55M-C$0.06N/A
Emblem$5.71M43.02-$24.81M-$0.19N/A

In the previous week, Helix BioPharma's average media sentiment score of 0.00 equaled Emblem'saverage media sentiment score.

Company Overall Sentiment
Helix BioPharma Neutral
Emblem Neutral

Summary

Emblem beats Helix BioPharma on 5 of the 8 factors compared between the two stocks.

How does Helix BioPharma compare to Theratechnologies?

Helix BioPharma (TSE:HBP) and Theratechnologies (TSE:TH) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, dividends, analyst recommendations, profitability, valuation, risk, earnings and media sentiment.

0.0% of Helix BioPharma shares are owned by institutional investors. Comparatively, 0.5% of Theratechnologies shares are owned by institutional investors. 2.2% of Helix BioPharma shares are owned by company insiders. Comparatively, 1.2% of Theratechnologies shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Helix BioPharma
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
Theratechnologies
0 Sell rating(s)
1 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
2.00

In the previous week, Theratechnologies had 1 more articles in the media than Helix BioPharma. MarketBeat recorded 1 mentions for Theratechnologies and 0 mentions for Helix BioPharma. Helix BioPharma's average media sentiment score of 0.00 equaled Theratechnologies'average media sentiment score.

Company Overall Sentiment
Helix BioPharma Neutral
Theratechnologies Neutral

Helix BioPharma has a beta of 0.403644, indicating that its share price is 60% less volatile than the broader market. Comparatively, Theratechnologies has a beta of 0.256166, indicating that its share price is 74% less volatile than the broader market.

Helix BioPharma has a net margin of 0.00% compared to Theratechnologies' net margin of -19.83%. Theratechnologies' return on equity of 47.31% beat Helix BioPharma's return on equity.

Company Net Margins Return on Equity Return on Assets
Helix BioPharmaN/A -36.79% -279.98%
Theratechnologies -19.83%47.31%5.15%

Theratechnologies has higher revenue and earnings than Helix BioPharma. Helix BioPharma is trading at a lower price-to-earnings ratio than Theratechnologies, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Helix BioPharmaN/AN/A-C$50.55M-C$0.06N/A
TheratechnologiesC$84.38M2.44-C$1.96M-C$0.19N/A

Summary

Theratechnologies beats Helix BioPharma on 8 of the 12 factors compared between the two stocks.

Get Helix BioPharma News Delivered to You Automatically

Sign up to receive the latest news and ratings for HBP and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

Media Sentiment Over Time

This chart shows the average media sentiment of TSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

HBP vs. The Competition

Export
MetricHelix BioPharmaBiotechnology IndustryMedical SectorTSE Exchange
Market CapC$124.50MC$470.59MC$6.46BC$12.16B
Dividend Yield1.50%3.87%2.76%6.20%
P/E Ratio-27.173.8621.2137.64
Price / SalesN/A7,288.62554.3811.68
Price / Cash11.3213.1343.4982.29
Price / Book8.1084.7810.374.50
Net Income-C$50.55M-C$96.07MC$3.57BC$299.09M
7 Day Performance3.16%0.04%6.40%2.48%
1 Month Performance-16.41%0.56%3.53%1.47%
1 Year Performance71.58%63.39%34.04%53.55%

Helix BioPharma Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
HBP
Helix BioPharma
N/AC$1.63
flat		N/AN/AC$124.50MN/AN/A9
FRX
Fennec Pharmaceuticals
0.0594 of 5 stars		C$13.31
flat		N/AN/AC$462.35MC$51.00MN/A10
PLI
ProMetic Life Sciences
N/AN/AN/AN/AC$317.06MC$39.91MN/A487
ABCN
VIVO Cannabis
N/AC$1.32
+5.6%		N/A+0.0%C$256.62MN/AN/AN/A
EMC
Emblem
N/A$1.88
+1.6%		N/A+0.0%$245.45M$5.71MN/AN/A

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (TSE:HBP) was last updated on 5/26/2026 by MarketBeat.com Staff.
From Our Partners
Hey, it's Jon Najarian. The SpaceX IPO is right around the corner. But I discovered Elon may have something BIGGER planned. Check this out before June 9th...
After being invited to the SpaceX launch headquarters in Cape Canaveral from one of Elon's top lobbyists… Hall...
Banyan Hill Publishing | Sponsoredtc pixel
The SpaceX supplier that shipped 5 billion chips to Starlink
When Nvidia surged 770%, its data center cooling supplier Vertiv climbed 1,700%. When Apple ran 2,000%, suppli...
Weiss Ratings | Sponsoredtc pixel
Trump Admin to Pump $1 Billion into this “Off-the-Radar” AI Stock
The U.S. government pumped more than $1 billion into Intel. The stock popped 128%. It pumped $400 million into...
InvestorPlace | Sponsoredtc pixel
Better than SpaceX? Grab this ticker instead.
Larry Benedict generated $274 million for his clients by finding the trades most investors missed. Now he says...
Brownstone Research | Sponsoredtc pixel
SpaceX will mint billionaires. You won't be one of them.
By the time a company goes public, 95% of profits have already been made. Insiders bought SpaceX at $20 billio...
Behind the Markets | Sponsoredtc pixel
Your book attached
Bill Poulos is offering his 'Simple Options Trading For Beginners' guide at no cost - normally priced at $29.9...
Profits Run | Sponsoredtc pixel
Gold surged 600 dollars last time this indicator peaked
The Buffett Indicator has predicted every major gold bull run this century - 2000, 2008, and 2020, when gold s...
Porter & Company | Sponsoredtc pixel
Opportunity Forming in a U.S. Supply-Chain Weak Spot?
America has a supply-chain problem with graphite - demand is climbing while dependence on foreign sources rema...
i2i Marketing Group, LLC | Sponsoredtc pixel